Tarsus Pharmaceuticals (TARS) Short-term Investments (2019 - 2025)

Tarsus Pharmaceuticals' Short-term Investments history runs 7 years deep, the most recent figure standing at $560000.0 for Q4 2025.

• On a quarterly basis, Short-term Investments fell 99.72% year-over-year to $560000.0 in Q4 2025; TTM through Dec 2025 was $560000.0, a 99.72% decrease from a year earlier, with the FY2025 full-year figure at $560000.0, down 99.72% from the prior year.
• Short-term Investments fell to $560000.0 in Q4 2025 per TARS's latest filing, from $289.1 million in the prior quarter.
• Across five years, Short-term Investments topped out at $289.1 million in Q3 2025 and bottomed at $20000.0 in Q1 2021.
• The 5-year median for Short-term Investments is $104.8 million (2024), against an average of $107.3 million.
• Across the five-year window, Short-term Investments surged 46368.04% in 2023 and slumped 99.72% in 2025, its largest moves.
• Year by year, Short-term Investments stood at $483000.0 in 2021, then surged by 29996.48% to $145.4 million in 2022, then sank by 98.28% to $2.5 million in 2023, then jumped by 7778.04% to $196.6 million in 2024, then slumped by 99.72% to $560000.0 in 2025.
• Per Business Quant, the three latest TARS Short-term Investments figures stand at $560000.0 (Q4 2025), $289.1 million (Q3 2025), and $284.5 million (Q2 2025).